TABLE 4.

Details of TRALI cases

Case	Arm	Age/sex	Admitting diagnosis	LAPS-II component*	Donor HLA antibody specificity	Recipient HLA type	Clinical TRALI noted†	Reaction reported to transfusion service	Other components transfused within 6 hr		Posttransfusion fluid balance
									Plasma	All
1	Study	69/F	Renal Ca surgery	Plasma	DQ7	NA	No	No	5	28	Pos
2	Study‡	58/M	Thoracic aorta dissection	Plasma	DR10,DR53§	NA	Yes	Yes	5	20	NA
3	Study‡	21/M	Spinal surgery	PLT	A68	NA	Yes	Yes	22	30	Pos
4	Study	39/M	Abdominal surgery	Plasma	Multiple∥	NA	No;  ARDS	No	1	1	Pos
5	Study	78/F	Subdural hematoma	Plasma	DR3¶	A2,A74  B53,B72  DR13,DR52  DQ6, DQ7	Yes	Yes	1	1	Neg
6	Study	79/M	Subdural hematoma	Plasma	DR3,DR7,DR8,DR11,DR12,DR13	NA	No	No	1	2	Neg
7	Study	70/F	Liver transplant	Plasma	B8, B15, B37, B57, DR3¶	A1, B8, DR17, DQ2	No	No	1	15	Pos
8	Control	58/M	Alcohol enceph and acute renal failure	Plasma	Negative	NA	No	No	0	0	Neg
9	Control	82/F	GI bleed	Plasma	Negative	NA	Yes	Yes	1	1	Neg

^*Eight LAPS-II components were from females with three or more pregnancies and one was from a donor with two pregnancies. Three cases received index LAPS-II components, three received subsequently donated components, and three received previously donated components.

^†All cases except Case 8 required mechanical ventilation. In-hospital death occurred in Cases 1 and 5. Frothy endotracheal tube secretions were observed in Cases 3 and 6.

^‡These two recipients were also part of the NHLBI SCCOR prospective TRALI study.

^§The HLA antibody screening assay was strongly positive for Class I antibody but the SAB assay failed to define a Class I specificity.

^∥The multiple antibody specificities were B13, B15, B27, B41, B44, B45, B46, B40, B47, B49, B50, B53, Cw1, Cw3, Cw4, Cw14, Cw18, DR3, DR8, DR11, DR12, DR13, DR14, DQ6, DQ8, DQ9; this donor also had a nonspecific HNA antibody.

^¶DR3 antibody crossreacts with DR13, DR52 (Case 5), and DR17 antigens (Case 7).

NA = not available.